Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730177 | 0.85 | PTPN1 (0.36) | THRBTDP1LMNAL3MBTL1TSHR | |
| SCHEMBL535650 | 0.83 | — | — | |
| SCHEMBL12895824 | 0.83 | — | — | |
| SCHEMBL9569071 | 0.83 | TRPV1 (0.39) | TDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL5702392 | 0.82 | LMNA (0.50) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL6706841 | 0.81 | TRPA1 (0.37) | THRBTDP1LMNAL3MBTL1TSHR | |
| SCHEMBL10461156 | 0.80 | LMNA (0.59) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL11923038 | 0.80 | LMNA (0.59) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL6058989 | 0.80 | LMNA (0.59) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL13638247 | 0.80 | LMNA (0.59) | TDP1LMNAL3MBTL1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018138591-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2007-02-01 | — | — | US | disclosed |
| EP-1273626-B1 | Aqueous resin composition, aqueous coating material containing the composition, coating provided by the material, and metal plate coated with the material | TOYO BOSEKI (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-6376713-B1 | REACTING A DIALCOHOL WITH AMMONIA | LONZA AG (CH) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | THRB 747/4885TDP1 4738/4885LMNA 3635/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | THRB 747/4885TDP1 4738/4885LMNA 3635/4885 |
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | ME1, ME2, SI | THRB 4627/4885TDP1 1981/4885LMNA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.